PROTECTIVE IMMUNITY IN MICE TO PNEUMOCOCCAL POLYSACCHARIDE PROTEIN

继续研究肺炎球菌的生化特征， 肺炎球菌自溶素与小鼠保护性免疫 多糖-蛋白质缀合物。 一些肺炎球菌的细胞表面 抗原被认为是毒力因子。 有几 蛋白质抗原和毒素，包括肺炎球菌溶血素、自溶素、肺炎球菌溶血素、 表面蛋白A（PspA）和其它次要抗原。 从肺炎球菌R61菌株分离并纯化。 自溶素表现出 N-乙酰胞壁酸L-丙氨酸酰胺酶的主要酶活性。 是 参与介导肺炎球菌溶血素从 细胞质 纯化后，自溶素的比活 增长143倍 产率为粗提物的0.9%。 它 在SDS-PAGE中显示单一条带，分子量为36，000。 肺炎球菌9V型PS或19 F型PS与载体蛋白的缀合 可产生足够抗体预防肺炎球菌感染 在童年时期。 溶血素和自溶素可能是有效的 用于PS-蛋白缀合物疫苗的载体。 细菌的研究 在免疫的年轻小鼠中继续清除和抗体应答 与9V型或19 F型PS-蛋白缀合物在生命早期， 检测幼鼠对肺炎球菌感染的保护性免疫力。 在其他研究中，19 F PS-ply缀合物在小鼠中诱导高19 F PS抗体。 年轻的小鼠通过RIA测量。 这些抗体诱导快速细菌 以5 × 104 cfu/剂量激发后，19 F细胞从血液中的清除率为 与未免疫的对照相比。

Studies were continued on biochemical characterization of pneumococcal autolysin and protective immunity in mice to pneumococcal polysaccharide-protein conjugates. A number of pneumococcal cell-surface antigens are considered to be virulence factors. There are several protein antigens and toxins including pneumolysin, autolysin, pneumococcal surface protein A (PspA) and other minor antigens.Autolysin was isolated from pneumococcal R61 strain and purified. The autolysin exhibits the major enzymatic activity of N-acetylmuramic acid L-alanine amidase. It is involved in mediating the release of pneumolysin from pneumococcal cytoplasm. After purification, the specific activity of autolysin increased 143 fold. The yield was 0.9% of the crude extract. It exhibited a single band in SDS-PAGE, having a molecular weight of 36,000. Conjugation of pneumococcal type 9V PS or type 19F PS to a carrier protein may produce sufficient antibody for prevention of pneumococcal infection during childhood. Pneumolysin and autolysin may serve as effective carriers for PS-protein conjugate vaccines. Studies on bacterial clearance and antibody response were continued in young mice immunized with type 9V or type 19F PS-protein conjugates during early life to examine the protective immunity of young mice to pneumococcal infection. In other studies, a 19F PS-ply conjugate induced high 19F PS antibodies in young mice as measured by RIA . These antibodies induced rapid bacterial clearance of 19F cells from blood after challenge with 5 x 104 cfu/dose as compared to the non-immunized controls.